Previous Article | Next Article 
Infect Immun, March 1998, p. 912-922, Vol. 66, No. 3
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Cytokine Kinetics and Other Host Factors in
Response to Pneumococcal Pulmonary Infection in Mice
Yves
Bergeron,
Nathalie
Ouellet,
Anne-Marie
Deslauriers,
Marie
Simard,
Martin
Olivier, and
Michel G.
Bergeron*
Centre de Recherche en Infectiologie, Centre
Hospitalier de l'Université Laval, and Département de
Microbiologie, Faculté de Médecine, Université
Laval, Québec, Canada G1V 4G2
Received 29 August 1997/Returned for modification 14 October
1997/Accepted 5 December 1997
 |
ABSTRACT |
There is a need for more insight into the pathogenesis of
Streptococcus pneumoniae pneumonia, as the fatality rate
associated with this disease remains high despite appropriate
antibiotherapy. The host response to pneumococci was
investigated after intranasal inoculation of CD1 mice with
107 log-phase CFU of bacteria. We identified five major
pathogenesis steps from initial infection to death. In step 1 (0 to
4 h), there was ineffective phagocytosis by alveolar macrophages,
with concurrent release of tumor necrosis factor alpha (TNF),
interleukin-6 (IL-6), and nitric oxide (NO) in bronchoalveolar lavage
(BAL) fluid, TNF, IL-6, and interleukin-1 alpha (IL-1) in lung tissues,
and IL-6 in serum, which were associated with tachypnea and
hemoconcentration. In step 2 (4 to 24 h), bacterial growth in
alveoli and polymorphonuclear cell recruitment from bloodstream to lung
tissue (high myeloperoxidase levels) to alveoli were associated with
high release of all three cytokines and leukotriene B4
(LTB4) in tissue and BAL fluid, as well as transient
spillover of IL-1 in serum. In step 3 (24 to 48 h), despite
downregulation of TNF and IL-1 in BAL fluid and lungs, there was
appearance of injury to alveolar ultrastructure, edema to interstitium,
and increase in lung weight as well as regeneration of type II
pneumocytes and increased secretion of surfactant; bacteria progressed
from alveoli to tissue to blood, and body weight loss occurred. In step
4 (48 to 72 h), strong monocyte recruitment from blood to alveoli
was associated with high NO release in tissue and BAL fluid, but there
was also noticeable lymphocyte recruitment and leukopenia; bacteremia
was associated with TNF and IL-6 release in blood and thrombocytopenia.
In step 5 (72 to 96 h), severe airspace disorganization, lipid
peroxidation (high malondialdehyde release in BAL fluid), and diffuse
tissue damage coincided with high NO levels; there was further increase in lung weight and bacterial growth, loss in body weight, and high
mortality rate. Delineation of the sequential steps that contribute to
the pathogenesis of pneumococcal pneumonia may generate markers of
evolution of disease and lead to better targeted intervention.
 |
INTRODUCTION |
The fatality rate associated with
Streptococcus pneumoniae still approximates 23% despite the
use of potent antibiotics and aggressive intensive-care support
(57). Death can occur days after initiation of antibiotic
therapy, when tissues are sterile and the pneumonia is clearing. There
is growing evidence that aspects of the immune response greatly
contribute to the high mortality rate: while immunosuppressed patients
die as a consequence of poor host response, immunocompetent hosts face
overwhelming inflammatory reactions that contribute to tissue injury,
shock, and death (37, 69, 82, 88).
While most bacterium-induced pneumonia rodent models have been used to
evaluate antibiotic pharmacokinetics and efficacy (7, 8, 50, 59,
67, 84, 87), various elements of the host response, including
chemokines, pro- and anti-inflammatory cytokines, oxygen radicals,
blood components, and immune and nonimmune cells, have also been
characterized (10, 25, 45, 74, 77, 81, 86). Some
pathogenesis studies have focused on interactions between bacterial or
host factors, histological lesions, and edema (11, 19, 47,
78). However, thorough, detailed study of the inflammatory
response to pneumococci in the lung over time is difficult to access
from the diverse publications as a single time course evaluation of the
infection. Although cytokines have been found in bronchoalveolar lavage
(BAL) fluid or plasma of animals (77) or patients (20,
53, 61), little correlation has been made so far between cytokine
levels within lung tissue, BAL fluid, and serum simultaneously, time
course of the disease, and outcome of pneumonia. The chronology of
leukotriene release and inflammatory cell recruitment has not been
studied in association with kinetics of cytokines. In addition, nitric
oxide (NO) release and its relationship to histopathology during
pneumococcal pneumonia in mice have not been reported. This is the
first pathogenesis study that addresses each of these concerns through
extensive sets of data, thus providing new insights into the sequential pathogenesis of S. pneumoniae pneumonia which we hope will
help establish guidelines for therapy with biological response
modifiers.
(The results of this work have been presented in part elsewhere
[9a, 9b, 20a, 55a]).
 |
MATERIALS AND METHODS |
Pneumococcal pneumonia model.
Female CD1 Swiss mice (20 to
22 g) were used for all experiments. Pneumonia was induced with a
penicillin-susceptible clinical strain of S. pneumoniae
serotype 3 originally isolated by blood culture, monthly passaged in
mice for 1 year, and transparent in colonial morphology. The infection
was as previously described (8), with minor modifications.
Briefly, lightly anesthetized animals received an inoculum of
107 log-phase CFU of bacteria in 50 µl of
phosphate-buffered saline (PBS) applied at the tip of the nose and
involuntarily inhaled. To facilitate migration of the inoculum to the
alveoli, mice were held in a vertical position for 2 min. They had free
access to mouse chow and water throughout the experiment and were
exposed to alternate standardized light/dark periods of 14 h/10 h/day.
Experimental protocol.
Each group consisted of 12 infected
animals which were sacrificed at time zero (preinfection) and at 1, 2, 4, 12, 24, 48, 72, and 96 h postinfection. Blood, BAL fluid, and
lung tissue were sampled to determine cellular response and to quantify
inflammatory mediators. Microbiological counts were determined in blood
and lung tissue. Histopathology of lung tissue was also done. Twelve additional unsacrificed infected animals were used as controls to
monitor death rate.
Development of infection.
Body weight and mortality rate
were recorded every day following infection. Lung weight was noted in
every sacrificed animal. Piloerection, tachypnea, prostration, and
morbidity were also noted when present. Bacterial growth in lungs was
monitored by using a microbiological assay: lungs and heart were taken
together and weighed before and after blood removal with 20 ml of
sterile saline infused through the right ventricle until the effluent was clear; lungs were then homogenized with a Potter apparatus at a
ratio of 1 g/10 ml of a 50 mM potassium phosphate buffer (pH 6.5);
bacteria were quantified in 50 µl of this crude homogenate by plating
10-fold dilutions on sheep blood agar and incubating the plates for
18 h at 37°C in an atmosphere of 5% CO2.
Homogenates were then frozen for subsequent detection of inflammatory
mediators as described below. Progression of bacterial growth to the
bloodstream was monitored by sampling blood from the retro-orbital
sinus of the left eye with a heparinized capillary, followed by direct plating on sheep blood agar. Bacteremia was reported as the percentage of positive hemocultures after incubation for 18 h at 37°C in 5% CO2.
Hematological profile.
Blood was also deposited in
heparinized Microvette (Sarstedt, Montreal, Quebec, Canada) tubes and
analyzed with a Coulter counter for leukocytes, erythrocytes,
hemoglobin, hematocrit, and platelets. Differentiation of cell
populations was obtained after counting 100 leukocytes on a smear
stained with Wright reagent.
Histology.
A scoring system for histopathology of lung
tissue was derived from the work of Davis et al. (19).
Briefly, whole lungs were fixed in formalin, embedded in paraffin, and
then processed for light microscopy (10× objective) to quantify the
percentage of lung involved in the inflammatory process. Tissue
sections of inflamed areas were also fixed in glutaraldehyde followed
by osmium tetroxide and then processed for light (40× objective) and
electron microscopy according to standard methodology (9). A
scoring grid (inflammatory cells + hemorrhage + edema + tissue injury + regeneration) was used to quantify inflammation
(Table 1). The overall histopathologic
score was calculated as percentage of lung involvement × scoring
grid. Bacterial growth and phagocytosis were also estimated.
Inflammatory cells.
Leukocyte recruitment in alveoli was
determined by BAL. Briefly, animals were killed by decerebration, the
trachea was exposed and intubated with a catheter, and then repeated
1-ml injections of PBS (without calcium and anticoagulant) were made
until a total of 3 ml of BAL fluid was harvested. BAL fluid was
centrifuged at 1,200 rpm for 10 min, and supernatant was frozen at
80°C for subsequent analysis of inflammatory mediators. Cells in
the pellet were resuspended in PBS for quantification of leukocytes
with a hemacytometer, and cell populations were enumerated from
Diff-Quick (catalog no. B4132-1; Baxter, Pointe-Claire, Québec,
Canada)-stained cytospin preparations. To avoid influence of a BAL on
cytokine levels in lung homogenates and to allow rapid removal of blood from tissues for the dosage of myeloperoxidase (MPO), BALs were performed in six mice per group per time, while six of the infected mice were sacrificed for sampling of tissues.
Neutrophil (polymorphonuclear cell [PMN]) infiltration in lung tissue
was quantified by the measurement of MPO as follows. Mice were
sacrificed, and lungs were removed, cleared of blood, and homogenized
in 50 mM potassium phosphate buffer (pH 6.5); to 100 µl of crude
homogenate was added 100 µl of hexadecyltrimethylammonium bromide to
achieve a final concentration of 0.5%; then homogenates were frozen at
80°C, thawed, sonicated for 30 s, and centrifuged at 6,000 rpm
in a microcentrifuge for 30 min at 4°C. MPO was evaluated by adding
150 µl of homogenate supernatant to 825 µl of phosphate buffer, 75 µl of o-dianisidine at 1.25 mg/ml of distilled water, and
75 µl of hydrogen peroxide at 0.05%. The enzymatic reaction was
stopped after 15 min by addition of 75 µl of 1% sodium azide, and
absorbance was read at 450 nm against a standard curve made with
commercial MPO (catalog no. M-6908; Sigma, Mississauga, Ontario, Canada).
Inflammatory mediators.
Tumor necrosis factor alpha (TNF),
interleukin-1 alpha (IL-1), and IL-6 levels were detected in the
supernatant of BAL fluid, in the supernatant of lung homogenates, and
in sera of control and infected animals. Lung homogenates were prepared
in potassium phosphate buffer as described above. To 600 µl of crude
homogenate was added 600 µl of phosphate buffer containing aprotinin
(20 U) and 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS; 0.2%), and samples were then frozen at
80°C. After
thawing, samples were centrifuged at 6,000 rpm in a microcentrifuge for 30 min at 4°C, and mouse enzyme-linked immunosorbent assay kits were
used to detect all cytokines in supernatants (TNF, IL-1, and IL-6;
catalog no. 80-2802-00, 1900-01, and 80-3748-01, respectively; Genzyme
Corporation, Cambridge, Mass.). Procedures for the assays were provided
with the commercial kits. Serum was obtained by centrifuging blood for
10 min at 4°C in a microcentrifuge at maximal speed.
Leukotriene B4 (LTB4) assay was also performed
in BAL supernatant, lung homogenate supernatant, and serum.
LTB4 levels were quantified by radioimmunoassay kits after
acidification of all samples to pH 3.5 with HCl, followed by extraction
of lipids with ethyl acetate. LTB4 in extracted material
was detected as instructed for the commercial product (catalog no.
8-6020; Cedarlane, Hornby, Ontario, Canada).
The release of NO in BAL supernatant, lung homogenate supernatant, and
serum was evaluated through measurement of its oxidized nitrite and
nitrate metabolites by the colorimetric method of Griess
(28).
Biochemistry.
Injuries to cell membranes were monitored
through the measurement of malondialdehyde (MDA), a metabolite
resulting from lipid peroxidation, which we detected by the method of
Ohkawa et al. (56) after slight modifications. Briefly, 0.2 ml of BAL supernatant, lung homogenate supernatant, or serum was added
to 0.2 ml of 8.1% sodium dodecyl sulfate 1.5 ml of 20% acetic acid
(pH 3.5), 1.5 ml of 0.8% thiobarbituric acid, and 0.6 ml of distilled
water. The mixture was heated for 1 h at 100°C, and then 1 ml of
water and 5 ml of butanol-pyridine (15:1) were added and the tubes were vigorously shaken. The upper organic phase obtained after
centrifugation for 10 min at 4,000 rpm was read at an absorbance of 532 nm. We calculated the amount of MDA present in the samples after
establishing a standard curve with 1,1,3,3-tetramethoxypropane which in
the above experimental conditions yields MDA in a 1:1 molecular ratio.
Total protein content, an indirect test measuring vascular permeability
and tissue injury which allow proteins to diffuse from capillaries to
tissues, was verified in BAL supernatant and lung homogenate
supernatant. Dosages were determined by the Bradford colorimetric
method with Coomassie blue (catalog no. 23200; Pierce, Rockford, Ill.)
as the reagent (42).
Statistical analysis.
All statistical analyses were
performed with StatView SE+ Graphics (Abaccus Concepts Inc., Berkeley,
Calif.). Statistical analysis of the difference between groups was
performed by analysis of variance using a least-squares method. If the
F test indicated a difference within groups
(P < 0.05), group comparisons were performed by
Fisher's protected least significant difference test, and
P < 0.05 was considered significant. All data are
presented as means ± standard errors of the means (SEM).
 |
RESULTS |
Mouse infection model.
Inoculation of mice with
107 S. pneumoniae cells resulted in a
transient hyperdynamic state of the animals, with tachypnea and
piloerection observable 4 h after infection. Animals apparently recovered for a while but then developed a gradually pronounced hypodynamic state (lifeless behavior, prostration) which was associated with gradual loss in body weight from 24 h until death. Body
weight fell from 20.0 g to 18.0, 16.8, 15.2, and 14.2 g at 0, 24, 48, 72, and 96 h, respectively. Although 21% of the animals
died as early as 48 h after infection, death usually occurred at
72 h (50%) or later (29%). The early and late physiological
manifestations were associated with hematological disorders such as
hemoconcentration at 4 h (14.6% increase in hematocrit
compared to controls at 0 h; P < 0.01) and
thrombocytopenia at 72 h (21.5% decrease compared to controls;
P < 0.05) but also with immunological and
microbiological phenomena described below.
After an initial stabilization of bacterial growth over the first
4 h at 106 CFU/g, which may be related to mechanical
and immune barriers against infection, bacterial counts in lung
homogenates increased to 107 CFU/g and were maintained at
that level for 60 h. They culminated at extremely high levels at
96 h (>108 CFU/g), which is quite comparable to the
levels recovered by other investigators at the time of death
(7). Hemocultures became positive at 24 h, with 83% of
the animals developing bacteremia between 24 and 48 h and 100%
demonstrating it between 72 and 96 h.
Histopathology.
Morphological examination of lungs
showed progressive edema and hepatization of tissues; i.e., the
gross appearance of the lungs resembled that of the liver due to
passage of blood elements from capillaries to tissues. These
modifications were associated with intense inflammatory response,
tissue injury, and increased lung weight. In fact, lung weight
increased from 183 ± 10 mg at time zero to 258 ± 11 mg at
24 h (P < 0.01); there was a plateau from 24 to
48 h, followed by an increase to 326 ± 9 mg at 72 h (P < 0.01 between 48 and 72 h) and a second
plateau until death. Histopathological examination by light
microscopy revealed progressive involvement of the whole lung surface
by the inflammatory process (Table
2). Initial foci of inflammation (<24 h)
were restricted to perivascular areas localized close to infected
bronchioles. Progressive parenchymal involvement including interstitial
edema, hemorrhage, modification in alveolar ultrastructure, and
proliferation of type II pneumocytes appeared over the 24- to 48-h
period in all lobes of the left and right lungs and progressed from
inner to outer areas until 60 to 75% of the whole lung surface showed signs of alteration. Finally, widespread inflammation and tissue injury
characterized the 72- to 96-h period, with 100% of the lung surface
being involved (Fig. 1).

View larger version (178K):
[in this window]
[in a new window]
|
FIG. 1.
Light and electron microscopy of lung architecture of
normal mice (A to C) and mice infected with 107 S. pneumoniae cells and sacrificed 72 h later (D to F).
Perivascular areas (arrowheads) close to bronchioles (B) (A and D;
magnification, ×400) were greatly enlarged after infection, due to
edema and phagocyte recruitment. Interstitial tissues (I) in alveolar
areas (B and E; ×400) were also enlarged, and leukocytes (L) could be
seen in alveoli. Tissue injury characterized the infectious and
inflammatory processes (C and F; ×5,000). Macrophages (M) containing
ingested bacteria (arrowhead) were seen, as well as recruited
neutrophils (N) and lymphocytes (LY). T1, type I
pneumocyte; T2, type II pneumocyte; E, endothelial cell.
|
|
Electron microscopy confirmed the increasing recruitment of phagocytic
cells in both tissue interstitium and alveoli over time, with PMNs
being progressively replaced by monocytes and a few lymphocytes at 72 to 96 h. Erythrocytes in alveoli were so abundant at 72 to 96 h that they became visible in BAL fluid. Tissue edema became so intense
at this same period that alveoli could hardly be distinguished in
tissue sections, and breathing of the animals became laborious. Type II
pneumocytes proliferated and secreted increased amount of surfactant in
alveolar spaces (Fig. 2A and C).
Widespread disorganization of lung architecture characterized the 72- to 96-h observations, and the presence of numerous collagen fibers
possibly indicated a scarring process initiated by fibroblasts.

View larger version (158K):
[in this window]
[in a new window]
|
FIG. 2.
Electron microscopy of lungs of mice infected with
107 S. pneumoniae cells and sacrificed 72 h
later. Type II pneumocytes (T2) proliferated after
infection (A; magnification, ×9,600) and secreted abnormal amounts of
surfactant (S) in alveoli (C; ×6,000). Although S. pneumoniae cells (arrows) were partly eradicated through
phagocytosis (M, macrophage) (B; ×18,000), extracellular killing also
seemed to occur, as the polysaccharide capsule (C) of bacteria
localized outside phagocytes in areas of intense inflammation appeared
more disaggregated (thinner and more diffuse) (B [arrows] and inset;
×44,000) than the capsule of bacteria localized in less severely
inflamed areas (D [×18,000] and inset [×44,000]). LY,
lymphocyte.
|
|
Phagocytosis of pneumococci both by macrophages and PMNs was noted.
Moreover, extracellular killing due to release of toxic components by
phagocytes or other host cells seemed to happen, as the polysaccharide
capsule of many bacteria localized outside phagocytes in areas of
intense inflammation appeared more disaggregated (thinner and more
diffuse; Fig. 2B and inset) than the capsule of bacteria localized in
less severely inflamed areas (Fig. 2D and inset).
Inflammatory cells.
Recruitment of inflammatory cells from
blood vessels to lung tissue and alveoli was monitored over time (Fig.
3). PMNs increased significantly in blood
(Fig. 3C), lung tissue (Fig. 3B), and BAL fluid (Fig. 3A) as early as 2 to 4 h after infection and reached high levels at 24 h in all
samples. Their numbers decreased gradually in blood and lung tissue
thereafter while remaining elevated in BAL fluid until death of the
animals. Monocyte/macrophage and lymphocyte levels decreased steadily
in blood until death (Fig. 3C), as both populations moved to BAL fluid
later (
48 h) than PMNs (Fig. 3A). Therefore, strong variations in
individual cell populations occurred over time, despite an apparent
constant number of total leukocytes in blood samples over the first
24 h (Fig. 3C). When comparing data for mice and humans, one must
remember that the blood of normal CD1 mice is composed of approximately 67% lymphocytes, 12% PMNs, and 19% monocytes.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 3.
Recruitment of inflammatory cells from blood vessels (C)
to lung tissue (B) to BAL (A) as a function of time after intranasal
infection with 107 S. pneumoniae cells. Cell
populations (mean ± SEM) in blood and BAL fluid were counted, and
neutrophils in lung homogenate were measured by quantifying MPO. *,
P < 0.05 compared with preinfection values; +,
P < 0.01 compared with preinfection values.
|
|
Inflammatory mediators.
Cytokine levels are reported in Fig.
4. TNF was the first cytokine to be
recovered in BAL fluid, with a significant increase from 1 to 12 h
compared with preinfection values (Fig. 4A). The appearance of this
cytokine in BAL fluid was transient despite progression of the
infectious process, as TNF rapidly dropped to normal values after
12 h. TNF release in lung tissue reached extremely high levels
(34,388 pg/g at 12 h), which may represent the participation of
interstitial inflammatory cells as well as noninflammatory cells (Fig.
4B). TNF was absent or detected in very low levels in serum until 48 and 72 h, and then a rapid increase was noted (Fig. 4C). This
increase closely coincided with the migration of bacteria to the
bloodstream. Taken together, these results clearly demonstrate
compartmentalization of TNF secretion to the site of infection, with
successive appearances in BAL, lung tissue, and finally blood.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 4.
Mean (SEM) cytokine levels in cell-free BAL, lung
homogenates previously cleared from blood, and serum of mice infected
with 107 S. pneumoniae cells. TNF in BAL (A),
lung (B), and serum (C), IL-1 in BAL (D), lung (E), and serum (F), and
IL-6 in BAL (G), lung (H), and serum (I) are reported. *,
P < 0.05 compared with preinfection values; +,
P < 0.01 compared with preinfection values.
|
|
A sustained IL-1 release was observed in lung tissue
throughout the experiment (Fig. 4E) combined with a very transient
appearance of this cytokine in cell-free BAL and serum at 12 h
(Fig. 4D and F). Both TNF and IL-1 peaked at 12 h in BAL and lungs
(Fig. 4A, B, D, and E), a time that preceded bacterial dissemination to blood vessels, which might incriminate these cytokines in the breaking
of the alveolo-capillary barrier.
IL-6 levels increased significantly very early in BAL and lung tissue
after infection (2 h), with a peak at 4 h that also corresponds
with partial release of IL-6 in serum (Fig. 4G to I). They remained
elevated quite constantly throughout the experiment. In fact, serum
levels indicated two episodes for circulating IL-6 (Fig. 4I): an early
brief appearance at 4 h, and a late sustained production from
48 h until death which correlates with bacteremia.
LTB4 levels, which were higher in BAL fluid than in the
lung, increased in cell-free BAL fluid from 12 to 72 h and in lung tissue at 24 h (Fig. 5A and B),
which accompanied and followed, rather than preceded, PMN
recruitment. The amount of LTB4 recovered in serum
decreased significantly over time (Fig. 5C), as did the number of
monocytes and other secretory inflammatory cells in whole blood (Fig.
3C).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
Mean (SEM) LTB4 levels in cell-free BAL (A),
in lung homogenates previously cleared from blood (B), and in serum (C)
of mice infected with 107 S. pneumoniae
cells. *, P < 0.05 compared with preinfection
values; +, P < 0.01 compared with preinfection
values.
|
|
A reduction in NO release was observed in serum of infected animals
throughout the experiment (Fig. 6C). By
contrast, a brief spontaneous release of NO was noted in BAL shortly
(1 h) after infection (Fig. 6A), at a time when only alveolar
macrophages are harvested in BAL. A second sustained phase (mostly 48 to 72 h) of high NO secretion in lung tissue (Fig. 6B) and BAL
(Fig. 6A) corresponded with the massive monocyte/macrophage recruitment period (Fig. 3A). Tissue injuries responsible for, or resulting from,
these high NO levels were noticed during the same period (Fig. 1 and
2).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 6.
Mean (SEM) NO levels in cell-free BAL (A), in lung
homogenates previously cleared from blood (B), and in serum (C) of mice
infected with 107 S. pneumoniae cells. *,
P < 0.05 compared with preinfection values; +,
P < 0.01 compared with preinfection values.
|
|
Although oxygen radicals and their oxidative potential for cell
membranes were not directly measured, lipid metabolites resulting from
membrane peroxidation were detected through MDA production. The release
of large amounts of MDA in the alveolar environment was noted at
96 h (Fig. 7). No increase was noted
in sera of infected and uninfected animals.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 7.
Mean (SEM) MDA levels in BAL 12 and 96 h after
infection with 107 S. pneumoniae cells. *,
P < 0.05 compared with preinfection values; +,
P < 0.01 compared with preinfection values.
|
|
Protein levels increased significantly throughout the experiment, from
4 to 72 h in cell-free BAL fluid and from 12 to 96 h in
lung homogenates (P < 0.05; data not shown).
 |
DISCUSSION |
Modern therapeutic approaches in infectious diseases have focused
on modulation of the host response (63). However, extensive data which correlate histopathology and overall inflammatory response in BAL fluid, lung tissue, and blood of patients suffering from bacterial pneumonia cannot be easily obtained. To better characterize the chronology of events associated with fatal pneumococcal pneumonia, we developed a murine model which allowed us to identify five major
pathogenesis steps from initial infection to death. The first two steps
corresponded to pulmonary infection in the absence of bacteremia, the
third step coincided with transition from pulmonary to systemic
infection, and the last two steps were characterized by widespread
overwhelming inflammatory reactions that led to severe tissue injuries,
hematological and biochemical disorders, and death. In step 1 (between
0 and 4 h after infection), there was partial but ineffective
bacterial clearance by resident alveolar macrophages, accompanied by
the activation of cytokines (TNF and IL-6 in BAL fluid; TNF, IL-6, and
IL-1 in lung tissues; IL-6 in serum) and transient NO release in BAL
fluid, which led to physiological and hematological anomalies. In step
2 (between 4 and 24 h), there was bacterial growth in alveoli and
recruitment of PMNs from bloodstream to lung tissue and alveoli,
associated with high release of all three cytokines and
LTB4 at the infected site and transient spillover of IL-1
in serum. In step 3 (between 24 and 48 h), there was
downregulation of proinflammatory cytokines (TNF and IL-1) in BAL fluid
and lungs, but tissue injuries became visible (loss of alveolar
ultrastructure, edema to interstitium, increase in lung weight) and
regeneration processes started (proliferation of type II pneumocytes,
increased secretion of surfactant), concomitant with progression of
bacteria to tissue and blood and noticeable loss in body weight. In
step 4 (between 48 and 72 h), overall infection and inflammation
were characterized by sharp reduction in blood leukocytes and gradual recruitment of monocytes and lymphocytes to BAL fluid; LTB4
and NO levels were very low in serum but increased in BAL fluid, thus corresponding to the monocyte migration; bacteremia was associated with
activation of cytokines (TNF and IL-6) but also with a sharp decrease
in platelet counts. In step 5 (between 72 and 96 h), pulmonary
histopathological features included severe airspace disorganization
with no remaining alveolar architecture and diffuse tissue damage that
coincided with high NO and MDA levels recovered in BAL fluid; lung
weight further increased; there was unrestrained bacterial growth, loss
in body weight, and a high mortality rate.
In our study, resident alveolar macrophages and successive waves of
PMNs, monocytes, and lymphocytes failed to eradicate S. pneumoniae. Pneumococci proliferated and induced bacteremia in addition to the initial pulmonary infection. In immunocompetent humans
coincidence of pneumonia and bacteremia ranges from 30 to 50% in the
absence of antibiotherapy, varying with serotype and the population
studied (10). The clinically isolated virulent strain that
we used allowed us to investigate both aspects of the infection, as
100% of the mice became bacteremic over time. The presepticemic and
septicemic phases of infection were clearly manifested in the
successive localization of TNF secretion to BAL fluid and blood,
respectively. Confinement of TNF to the site of infection in rats after
intratracheal or intravenous injection of endotoxin (55),
and in patients suffering from unilobar pneumonia (20), has
been reported. The downregulation of TNF in BAL fluid after 48 h
despite sustained stimulation by bacterial components also corroborates
other data from septicemic animals (70). In the context of
pneumococcal pneumonia, TNF measurement may thus prove useful for
monitoring the presepticemic and septicemic phases of pneumonia.
Additional prognostic factors that appeared to behave similarly in mice
and humans include thrombocytopenia and leukopenia, which coincided
with bacteremia and death in our model and which are also considered
useful negative prognostic factors in community-acquired pneumonia and sepsis (36, 54, 61). Although thrombocytopenia may have resulted from interactions of platelets with bacterial toxins, endogenous cytokines also contribute to coagulation anomalies and disseminated intravascular coagulation that sometimes accompany sepsis (2, 36).
In our model, blood levels of cytokines did not reflect appropriately
tissue levels (and ongoing tissue injury), as the latter remained
extremely high throughout the experiment while the former showed
transient appearance only. The sporadic release of TNF, IL-1, and IL-6
in blood has been observed in other experimental models as well as in
patients (20, 33, 53, 61). These observations might explain
the discrepancies in the literature concerning the attempts to
correlate outcome of pneumonia with cytokine levels. Blood analysis
should be interpreted in terms of overall chronological events that
mediate pathogenesis of pneumonia. As an example, high levels of TNF
and IL-6 in blood at the same time in our model indicated fully
developed infection with bacteremia (which possibly contributed to
activating cytokines from blood elements); by contrast, increased IL-6
levels in blood in the absence of TNF indicated early disease with
limited tissue injury and no bacteremia. According to Puren et al.
(61), IL-6 probably reflects severity of stress rather than
severity of infection during community-acquired pneumonia; the early
high blood IL-6 level in our experiment (4 h) provides support for this
hypothesis, as it coincides with early exposure of airways to
pneumococci and with early physiological derangements including
piloerection and tachypnea.
Monitoring of inflammatory mediators in BAL might also generate markers
of evolution of disease, including cytokines, LTB4, and NO.
While IL-6 in BAL fluid is most likely a good indicator of early
infection, it did not reflect the evolution of infection and should not
be considered in this fluid as a good indicator of the progression of
the infectious process; the enhanced secretion of TNF, by contrast,
correlated with the initial inflammatory response localized to lungs in
the absence of systemic involvement. IL-1
, which exerts biologic
activity primarily in a membrane-associated form compared to IL-1
or
TNF (1), also transiently appeared in cell-free BAL and
serum at 12 h postinfection (a time when tissue
concentrations peaked at extremely high levels), suggesting a
spillover of IL-1 from cells to fluids when overproduction occurred. Detectable levels of IL-1 in serum or BAL fluid may thus indicate very
active inflammatory processes, mostly in tissues. Our data also show
that low TNF and IL-1 levels recovered in BAL fluid do not necessarily
indicate good health status, especially when LTB4 or NO is
detected in BAL fluid, but rather signify transition from step 2 to
steps 3 to 5 in the pathogenesis process and thus an evolution toward a
more profound illness state. NO succeeded to TNF in BAL as infection
and inflammation progressed. In fact, the combination of the profiles
of TNF in BAL and blood and NO in BAL provided an accurate estimation
of disease state which chronologically corresponded to worsening of
pathological score. They could therefore be viewed as good biological
markers for pneumonia, and antagonists should be investigated at
appropriate stages of infection in the context of immunotherapy.
To our knowledge, this is the first study to demonstrate NO release in
BAL fluid and tissue during pneumococcal pneumonia and to correlate it
with tissue injury and monocyte recruitment in BAL fluid. NO has been
reported to be secreted by alveolar and interstitial macrophages during
endotoxemia and Pneumocystis carinii pneumonia (75,
90) and to be required for protective immunity against
Klebsiella pneumoniae pneumonia (81). The
monocyte migration from bloodstream to alveoli in our study was
associated with decreased NO in blood and increased secretion in
alveoli, which provides support for monocytes/macrophages as the
main sources for NO during pneumococcal pneumonia. However, type II
pneumocytes, endothelial cells, fibroblasts, and lymphocytes can also
release NO (32, 48, 51, 60, 89). In fact, NO production in
BAL was biphasic: an early but transient release (1 h) may have
resulted from the activation of constitutive NO synthase by resident
alveolar macrophages, but the late (48 to 72 h) massive and
sustained release must have resulted from the activation of inducible
NO synthase in recruited monocytes and other cells.
Although several animal models have been used to demonstrate a role for
NO as an effector molecule for the killing of bacteria, parasites, and
fungi (reviewed in references 27, 46, and
81), we could not demonstrate from this experiment a
link between NO release and bacterial counts in tissue. However, both
phagocytosis of bacteria and destruction of the pneumococcal capsule
outside phagocytes were observed in areas of intense inflammation
compared to less inflamed areas. Extracellular oxygen radicals
(15, 22, 71) and NO may have helped restrain bacterial
growth. On the other hand, leakage of serum proteins to alveoli most
likely induced by NO may have served as a source of nutrients for
bacteria as well as a vehicle for their dissemination.
NO possibly has a multifaceted role in our model, ranging from
capillary leakage and edema (38, 43, 46) through modulation of leukocyte activity (23, 26, 44, 46) to tissue
cytotoxicity (3, 6, 51, 52, 72). NO may affect cell activity
by altering signal transduction, energy production, and DNA synthesis (48, 72). Reactive oxygen and nitrogen species also act in concert to induce lipid peroxidation, defective membrane permeability, and cell injury through the formation of peroxynitrites (31, 80). It is not surprising that in our experiment, NO
overproduction was associated with high histopathologic score, lipid
metabolite (MDA) release, and death. Blocking NO delays mortality
in our model (unpublished data), and this therapeutic approach
deserves further investigation. Antioxidants should also be
investigated as potential adjuvants to antibiotherapy of
pneumonia (6).
Other components of inflammatory response may have contributed to
tissue injury. These include some virulence factors such as
peptidoglycan-teichoic acid complex, which stimulates cytokine release
and edema (16, 39), and pneumolysin, which can create transmembrane pores in lipid bilayers of virtually every type of cell
in the lungs (10, 16, 64-66). Large numbers of immune and
nonimmune cells as well as of cytokines and chemokines have been
postulated to play important roles in the development or control of
inflammation (45, 69, 73). Although minimal TNF and IL-1
secretion has been associated with protective immunity in a number of
pulmonary disorders (4, 12, 18, 77, 85), their combination
also mediates several hemodynamic manifestations and cell toxicity
(24, 82), and they stimulate NO production (40, 44, 46,
90). Considering TNF- and IL-1-mediated epithelial cell
toxicities and PMN-induced tissue injury (88, 91), their concomitant activity at 12 to 24 h after infection, in association with bacterial virulence factors, may have initiated membrane injury
resulting thereafter in hemorrhage in BAL fluid, edema in tissue
interstitium, bacterial growth inside pneumocytes (79) and
further migration to bloodstream, and progressive loss in body weight.
Proliferation of type II pneumocytes followed, as a repair process to
regenerate both type II and type I epithelial cells (69).
While type I pneumocytes are very sensitive to PMN-induced cytotoxicity
(69), type II pneumocytes stimulated by IL-1 express surface
receptors for pneumococci, which contributes to infection (16,
17). Increased type II/type I ratio might play a role in the
outcome of pneumonia (62). As an example, the abundant surfactant release by type II cells possibly dampened inflammatory reactions, mostly by reducing proinflammatory cytokines levels in BAL
fluid (69).
The inflammatory cell influx in our model closely paralleled the
successive waves of PMNs, monocytes, and lymphocytes reported after
intratracheal administration of endotoxin, IL-1, or TNF in rats
(83). The kinetics of MPO in lung homogenates correlated with the observable PMNs on tissue sections. Also evidenced by our
experiment is the fact that LTB4 cannot be accounted for as the primary chemotactic substance for PMNs, as its synthesis paralleled and followed, rather than preceded, PMN influx to alveoli. Although mouse and human PMNs show a high reactivity to LTB4
(76), and LTB4 is elevated in various pulmonary
infections in animals and humans (35, 71, 75), we do not
exclude that LTB4 release in BAL may have partly reflected
an ongoing injury process to the alveolar barrier, as costimulation of
pneumocytes with PMNs results in an amplification of LTB4
generation (30, 69).
Several lines of evidence suggest that C-X-C and C-C chemokines may be
critically involved in PMN and monocyte recruitment in bacterial
infections. IL-8, in particular, has been detected in patients with
acute pulmonary infection (41, 74), and elevated BAL IL-8
levels correlated with fatal outcome (while plasma IL-8 levels did not)
(14). Macrophage inflammatory protein 2 is the likely
functional murine homologue of IL-8, as it performs the functions of
human IL-8 in mice (11, 29, 68). It has been associated with
lung PMN influx in K. pneumoniae pulmonary infection (74) and might play an important role in our model. The
beneficial versus detrimental effects of pneumococcal-induced lung PMN
influx in immunocompetent hosts, which may occur through
CD18-independent mechanisms (21, 34, 49, 58, 82), remain to
be better clarified.
Recruitment of monocytes to the lungs for clearance of debris usually
occurs once PMN activity declines and infection subsides (5). Many chemokines increase chemotaxis and
phagocytic activity of monocytes/macrophages (11,
74), and we do not exclude that PMNs may have secreted many of
these cytokines (13). However, in our model of untreated
fatal pneumonia, monocytes may have contributed to worsening tissue
damage, as noted by the recrudescence of LTB4, IL-6, and NO
secretion in BAL fluid and lung tissue and the increase in lung weight.
In conclusion, the five major pathogenesis steps that we identified
from initial infection to death involved the successive recruitment of
PMNs, monocytes, and lymphocytes, the pulmonary and/or systemic release
of inflammatory mediators that characterized the presystemic and
systemic phases of infection, and the participation of parenchymal
cells in the host response. Although the kinetics of cytokines differed
considerably from blood to lung tissue to alveoli and blood levels did
not correlate with tissue levels, the kinetics of TNF and IL-6 in blood
as well as TNF and NO in BAL were good indicators of the evolution of
the disease. NO release was biphasic and corresponded mostly to
monocyte recruitment in BAL and concomitant serious tissue injury.
Pneumococci activated leukotriene release, but PMN recruitment was not
primarily mediated by LTB4. Bacteremia, leukopenia,
thrombocytopenia, and lipid peroxidation (MDA in BAL fluid) closely
preceded death. Knowing the chronological inflammatory events that
occur during pneumonia may help in designing appropriate diagnostic
tests that could be used to monitor the evolution of this deadly
infection. We are seeing an explosion of biological response modifiers
which may be used to treat pneumonia. The proper use of these agents
will require prior identification of biological markers in humans
suffering from pneumonia.
 |
ACKNOWLEDGMENTS |
M.O. is a recipient of a Fonds de Recherche en Santé du
Québec Junior II scholarship.
We thank Denis Beauchamp for his kind participation in the project.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Centre de
Recherche en Infectiologie, Centre Hospitalier de l'Université
Laval, 2705 Boul. Laurier, Sainte-Foy, Québec, Canada G1V 4G2.
Phone: (418) 654-2705. Fax: (418) 654-2715. E-mail:
Michel.G.Bergeron{at}crchul.ulaval.ca.
Editor: J. M. Mansfield
 |
REFERENCES |
| 1.
|
Abbas, A. K.,
A. H. Lichtman, and J. S. Pober.
1991.
Effector mechanisms of immune responses. Cytokines, p. 232-235. In
M. J. Wonsiewicz (ed.), Cellular and molecular immunology. W. B.
Saunders Company, Philadelphia, Pa.
|
| 2.
|
Aihara, M.,
T. Nakazawa,
K. Dobashi,
T. Joshita,
M. Kojima,
M. Onai, and M. Mori.
1997.
A selective pulmonary thrombosis associated with sepsis-induced disseminated intravascular coagulation.
Intern. Med.
36:97-101[Medline].
|
| 3.
|
Akaike, T.,
Y. Noguchi,
S. Ijiri,
K. Setoguchi,
M. Suga,
Y. M. Zheng,
B. Dietzschold, and H. Maeda.
1996.
Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals.
Proc. Natl. Acad. Sci. USA
93:2448-2453[Abstract/Free Full Text].
|
| 4.
|
Amura, C. R.,
P. A. Fontan,
N. Sanjuan, and D. O. Sordelli.
1994.
The effect of treatment with interleukin-1 and tumor necrosis factor on Pseudomonas aeruginosa lung infection in a granulocytopenic mouse model.
Clin. Immunol. Immunopathol.
73:261-266[Medline].
|
| 5.
| Anderson, V. M., and T. Turner. 1991. Histopathology of childhood pneumonia in developing countries. Rev.
Infect. Dis. 13(Suppl. 6):S470-S476.
|
| 6.
|
Antonini, J. M.,
K. Van Dyke,
M. DiMatteo, and M. J. Reasor.
1995.
Attenuation of acute inflammatory effects of silica in rat lung by 21-aminosteroid, U74389G.
Inflammation
19:9-21[Medline].
|
| 7.
| Azoulay-Dupuis, E., J. P. Bedos, E. Vallée,
and J. J. Pocidalo. 1991. Comparative activity of fluorinated
quinolones in acute and subacute Streptococcus pneumoniae
pneumonia models: efficacy of temafloxacin. J. Antimicrob. Chemother.
28(Suppl. C):45-53.
|
| 8.
|
Azoulay-Dupuis, E.,
E. Vallée,
J. P. Bedos,
M. Muffat-Joly, and J. J. Pocidalo.
1991.
Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia.
Antimicrob. Agents Chemother.
35:1024-1028[Abstract/Free Full Text].
|
| 9.
|
Beauchamp, D.,
P. Gourde,
M. Simard, and M. G. Bergeron.
1994.
Subcellular distribution of daptomycin given alone or with tobramycin in renal proximal tubular cells.
Antimicrob. Agents Chemother.
38:189-194[Abstract/Free Full Text].
|
| 9a.
|
Bergeron, Y.,
N. Ouellet,
M. Simard,
M. Olivier, and M. G. Bergeron.
1997.
Immunotherapy of pneumococcal pneumonia with cefodizime, abstr. 15..
Abstracts of the 4th International Congress on Biological Response Modifiers.
The Inter-American Society for Chemotherapy, Imedex USA, Alpharetta, Ga.
|
| 9b.
| Bergeron, Y., A. M. Deslauriers, M. Olivier, M. Simard,
D. Beauchamp, and M. G. Bergeron. 1995. Novel strategies to
control the inflammatory response during lethal bacterial pneumonia.
Can. J. Infect. Dis. 6(Suppl. C):418C.
(Abstract.)
|
| 10.
|
Boulnois, G. J.
1992.
Pneumococcal proteins and the pathogenesis of disease caused by Streptococcus pneumoniae.
J. Gen. Microbiol.
138:249-259[Medline].
|
| 11.
|
Broug-Holub, E.,
G. B. Toews,
J. F. Van Iwaarden,
R. M. Strieter,
S. L. Kunkel,
R. Paine, and T. J. Standiford.
1997.
Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival.
Infect. Immun.
65:1139-1146[Abstract].
|
| 12.
|
Buret, A.,
M. L. Dunkley,
G. Pang,
R. L. Clancy, and A. W. Cripps.
1994.
Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats: roles of alveolar macrophages, tumor necrosis factor alpha, and interleukin-1 alpha.
Infect. Immun.
62:5335-5343[Abstract/Free Full Text].
|
| 13.
|
Cassatella, M. A.
1995.
The production of cytokines by polymorphonuclear neutrophils.
Immunol. Today
16:21-26[Medline].
|
| 14.
|
Chollet-Martin, S.,
P. Montravers,
C. Gibert,
C. Elbim,
J. M. Desmonts,
J. Y. Fagon, and M. Gougerot-Pocidalo.
1993.
High levels of interleukin-8 in the blood and alveolar spaces of patients with pneumonia and adult respiratory distress syndrome.
Infect. Immun.
61:4553-4559[Abstract/Free Full Text].
|
| 15.
|
Coonrod, J. D.,
R. Varble, and M. C. Jarrells.
1990.
Species variation in the mechanism of killing of inhaled pneumococci.
J. Lab. Clin. Med.
116:354-362[Medline].
|
| 16.
| Cundell, D., H. R. Masure, and E. I. Tuomanen. 1995. The molecular basis of pneumococcal infection: a
hypothesis. Clin. Infect. Dis. 21(Suppl.
3):S204-S212.
|
| 17.
|
Cundell, D. R., and E. I. Tuomanen.
1994.
Receptor specificity of adherence of Streptococcus pneumoniae to human type-II pneumocytes and vascular endothelial cells in vitro.
Microb. Pathog.
17:361-374[Medline].
|
| 18.
|
Czuprynski, C. J.,
M. Haak-Frendscho,
N. Maroushek, and J. F. Brown.
1992.
Effects of recombinant human interleukin-6 alone and in combination with recombinant interleukin-1 alpha and tumor necrosis factor alpha on antibacterial resistance in mice.
Antimicrob. Agents Chemother.
36:68-70[Abstract/Free Full Text].
|
| 19.
|
Davis, C. C.,
M. A. Mellencamp, and L. C. Preheim.
1991.
A model of pneumococcal pneumonia in chronically intoxicated rats.
J. Infect. Dis.
163:799-805[Medline].
|
| 20.
|
Dehoux, M. S.,
A. Boutten,
J. Ostinelli,
N. Seta,
M. C. Dombret,
B. Crestani,
M. Deschenes,
J. L. Trouillet, and M. Aubier.
1994.
Compartmentalized cytokine production within the human lung in unilateral pneumonia.
Am. J. Respir. Crit. Care Med.
150:710-716[Abstract].
|
| 20a.
| Deslauries, A. M., Y. Bergeron, M. Olivier, D. Beauchamp,
P. Gourde, and M. G. Bergeron. 1995. The role of host defense
mechanisms in a murine model of Streptococcus pneumoniae
pneumonia. Can. J. Infect. Dis. 6(Suppl. C):419C.
(Abstract.)
|
| 21.
|
Doerschuk, C. M.,
R. K. Winn,
H. O. Coxson, and J. M. Harlan.
1990.
CD18-dependent and -independent mechanisms of neutrophil emigration in the pulmonary and systemic microcirculation of rabbits.
J. Immunol.
144:2327-2333[Abstract].
|
| 22.
|
Dunne, D. W.,
D. Resnick,
J. Greenberg,
M. Krieger, and K. A. Joiner.
1994.
The type I macrophage scavenger receptor binds to gram-positive bacteria and recognizes lipoteichoic acid.
Proc. Natl. Acad. Sci. USA
91:1863-1867[Abstract/Free Full Text].
|
| 23.
|
Elferink, J. G. R., and B. E. VanUffelen.
1996.
The role of cyclic nucleotides in neutrophil migration.
Gen. Pharmacol.
27:387-393[Medline].
|
| 24.
|
Fahey, T. J.,
K. J. Tracey, and A. Cerami.
1992.
Tumor necrosis factor (cachectin) and the adult respiratory distress syndrome, p. 175-183. In
A. P. Fishman (ed.), Update: pulmonary diseases and disorders
McGraw-Hill, Montreal, Québec, Canada.
|
| 25.
|
Fox-Dewhurst, R.,
M. K. Alberts,
O. Kajikawa,
E. Caldwell,
M. C. Johnson, et al.
1997.
Pulmonary and systemic inflammatory responses in rabbits with gram-negative pneumonia.
Am. J. Respir. Crit. Care Med.
155:2030-2040[Abstract].
|
| 26.
|
Gaboury, J.,
R. C. Woodman,
D. N. Granger,
P. Reinhardt, and P. Kubes.
1993.
Nitric oxide prevents leukocyte adherence: role of superoxide.
Am. J. Physiol.
265(3 part 2):H862-H867[Abstract/Free Full Text].
|
| 27.
|
Gosselin, D.,
J. DeSanctis,
M. Boule,
E. Skamene,
C. Matouk, and D. Radzioch.
1995.
Role of tumor necrosis factor alpha in innate resistance to mouse pulmonary infection with Pseudomonas aeruginosa.
Infect. Immun.
63:3272-3278[Abstract].
|
| 28.
|
Green, L. C.,
S. R. Tannenbaum, and P. Goldman.
1981.
Nitrate synthesis in the germfree and conventional rat.
Science
212:56-58[Abstract/Free Full Text].
|
| 29.
|
Greenberger, M. J.,
R. M. Streiter,
S. L. Kunkel,
J. M. Danforth,
L. L. Laichalk,
D. C. McGillicudy, and T. J. Standiford.
1996.
Neutralization of MIP-2 attenuates neutrophil recruitment and bacterial clearance in murine Klebsiella pneumonia.
J. Infect. Dis.
173:159-163[Medline].
|
| 30.
|
Grimminger, F.,
I. Von Kurten,
D. Walmrath, and W. Seeger.
1992.
Type II alveolar epithelial eicosanoid metabolism: predominance of cyclooxygenase pathways and transcellular lipoxygenase metabolism in co-culture with neutrophils.
Am. J. Respir. Cell. Mol. Biol.
6:9-16.
|
| 31.
|
Gross, S. S., and M. S. Wolin.
1995.
Nitric oxide: pathophysiological mechanisms.
Annu. Rev. Physiol.
57:737-769[Medline].
|
| 32.
|
Gutierrez, H. H.,
B. R. Pitt,
M. Schwarz,
S. C. Watkins,
C. Lowenstein,
I. Caniggia,
P. Chumley, and B. A. Freeman.
1995.
Pulmonary alveolar epithelial inducible NO synthase gene expression: regulation by inflammatory mediators.
Am. J. Physiol.
268(3 part 1):L501-L508[Abstract/Free Full Text].
|
| 33.
|
Hennet, T.,
H. J. Ziltener,
K. Frei, and E. Peterhans.
1992.
A kinetic study of immune mediators in the lungs of mice infected with influenza A virus.
J. Immunol.
149:932-939[Abstract].
|
| 34.
|
Hogg, J. C., and C. M. Doerschuk.
1995.
Leukocyte traffic in the lung.
Annu. Rev. Physiol.
57:97-114[Medline].
|
| 35.
|
Hopkins, H.,
T. Stull,
S. Von-Essen,
R. A. Robbins, and S. I. Rennard.
1989.
Neutrophil chemotactic factors in bacterial pneumonia.
Chest
95:1021-1027[Abstract/Free Full Text].
|
| 36.
|
Jacobs, E. R., and R. C. Bone.
1986.
Clinical indicators in sepsis and septic adult respiratory distress syndrome.
Med. Clin. North Am.
70:921-932[Medline].
|
| 37.
| Johnston, R. B. J. 1991. Pathogenesis of
pneumococcal pneumonia. Rev. Infect. Dis. 13(Suppl.
6):S509-S517.
|
| 38.
|
Kageyama, N.,
M. Miura,
M. Ichinose,
M. Tomaki,
J. Ishikawa,
Y. Ohuchi,
N. Endoh, and K. Shirato.
1997.
Role of endogenous nitric oxide in airway microvascular leakage induced by inflammatory mediators.
Eur. Respir. J.
10:13-19[Abstract].
|
| 39.
|
Keller, R.,
W. Fischer,
R. Keist, and S. Bassetti.
1992.
Macrophage response to bacteria: induction of marked secretory and cellular activities by lipoteichoic acids.
Infect. Immun.
60:3664-3672[Abstract/Free Full Text].
|
| 40.
|
Kilbourn, R. G., and O. W. Griffith.
1992.
Overproduction of nitric oxide in cytokine-mediated and septic shock.
J. Natl. Cancer Inst.
84:827-831[Free Full Text].
|
| 41.
|
Krarup, E.,
J. Vestbo,
T. L. Benfield, and J. D. Lundgren.
1997.
Interleukin-8 and leukotriene B4 in bronchoalveolar lavage fluid from HIV-infected patients with bacterial pneumonia.
Respir. Med.
91:317-321[Medline].
|
| 42.
|
Kruger, N. J.
1994.
The Bradford method for protein quantitation.
Methods Mol. Biol.
32:9-15[Medline].
|
| 43.
|
Laszlo, F.,
B. J. Whittle,
S. M. Evans, and S. Moncada.
1995.
Association of microvascular leakage with induction of nitric oxide synthase: effects of nitric oxide synthase inhibitors in various organs.
Eur. J. Pharmacol.
283:47-53[Medline].
|
| 44.
|
Liew, F. Y.
1995.
Interactions between cytokines and nitric oxide.
Adv. Neuroimmunol.
5:201-209[Medline].
|
| 45.
|
Lukacs, N. W., and P. A. Ward.
1996.
Inflammatory mediators, cytokines, and adhesion molecules in pulmonary inflammation and injury.
Adv. Immunol.
62:257-291[Medline].
|
| 46.
|
Lyons, C. R.
1995.
The role of nitric oxide in inflammation.
Adv. Immunol.
60:323-355[Medline].
|
| 47.
|
Mellencamp, M. A., and L. C. Preheim.
1991.
Pneumococcal pneumonia in a rat model of cirrhosis: effects of cirrhosis on pulmonary defense mechanisms against Streptococcus pneumoniae.
J. Infect. Dis.
163:102-108[Medline].
|
| 48.
|
Miles, P. R.,
L. Bowman, and L. Huffman.
1996.
Nitric oxide alters metabolism in isolated alveolar type II cells.
Am. J. Physiol.
271(1 part 1):L23-L30[Abstract/Free Full Text].
|
| 49.
|
Mizgerd, J. P.,
B. B. Meek,
G. J. Kutkoski,
D. C. Biullard,
A. L. Beaudet, and C. M. Doerschuk.
1996.
Selectins and neutrophil traffic: margination and Streptococcus pneumoniae-induced emigration in murine lungs.
J. Exp. Med.
184:639-645[Abstract/Free Full Text].
|
| 50.
|
Moine, P.,
E. Vallée,
D. E. Azoulay,
P. Bourget,
J. P. Bedos,
J. Bauchet, and J. J. Pocidalo.
1994.
In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model.
Antimicrob. Agents Chemother.
38:1953-1958[Abstract/Free Full Text].
|
| 51.
|
Moncada, S., and A. Higgs.
1993.
The L-arginine-nitric oxide pathway.
N. Engl. J. Med.
329:2002-2012[Free Full Text].
|
| 52.
|
Moncada, S., and E. A. Higgs.
1991.
Endogenous nitric oxide: physiology, pathology and clinical relevance.
Eur. J. Clin. Invest.
21:361-374[Medline].
|
| 53.
|
Moussa, K.,
H. J. Michie,
I. A. Cree,
A. C. McCafferty,
J. H. Winter,
D. P. Dhillon,
S. Stephens, and R. A. Brown.
1994.
Phagocyte function and cytokine production in community acquired pneumonia.
Thorax
49:107-111[Abstract].
|
| 54.
|
Musher, D. M.
1992.
Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment.
Clin. Infect. Dis.
14:801-807[Medline].
|
| 55.
|
Nelson, S.,
G. J. Bagby,
B. G. Bainton,
L. A. Wilson,
J. J. Thompson, and W. R. Summer.
1989.
Compartmentalization of intraalveolar and systemic lipopolysaccharide-induced tumor necrosis factor and the pulmonary inflammatory response.
J. Infect. Dis.
159:189-194[Medline].
|
| 55a.
|
Ouellet, N.,
Y. Bergeron,
M. Simard,
M. Duong,
M. Olivier,
D. Beauchamp, and M. G. Bergeron.
1997.
Beneficial immunomodulation of pneumococcal pulmonary infection with NG-monomethyl-L-arginine, abstr. G-56..
Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy.
American Society for Microbiology, Washington, D.C.
|
| 56.
|
Ohkawa, H.,
N. Ohishi, and K. Yagi.
1979.
Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction.
Anal. Biochem.
95:351-358[Medline].
|
| 57.
|
Pallares, R.,
J. Linares,
M. Vadillo,
C. Cabellos,
F. Manresa,
P. F. Viladrich,
R. Martin, and F. Gudiol.
1995.
Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.
N. Engl. J. Med.
333:474-486[Abstract/Free Full Text].
|
| 58.
|
Pilewski, J. M., and S. M. Albelda.
1993.
Adhesion molecules in the lung. An overview.
Am. Rev. Respir. Dis.
148:S31-S37[Medline].
|
| 59.
|
Ponte, C.,
A. Parra,
E. Nieto, and F. Soriano.
1996.
Development of experimental pneumonia by infection with penicillin-insensitive Streptococcus pneumoniae in guinea pigs and their treatment with amoxicillin, cefotaxime, and meropenem.
Antimicrob. Agents Chemother.
40:2698-2702[Abstract].
|
| 60.
|
Punjabi, C. J.,
J. D. Laskin,
K. J. Pendino,
N. L. Goller,
S. K. Durham, and D. L. Laskin.
1994.
Production of nitric oxide by rat type II pneumocytes: increased expression of inducible nitric oxide synthase following inhalation of a pulmonary irritant.
Am. J. Respir. Cell. Mol. Biol.
11:165-172[Abstract].
|
| 61.
|
Puren, A. J.,
C. Feldman,
N. Savage,
P. J. Becker, and C. Smith.
1995.
Patterns of cytokine expression in community-acquired pneumonia.
Chest
107:1342-1349[Abstract/Free Full Text].
|
| 62.
|
Rhodes, G. C.,
A. W. Lykke,
J. W. Tepsell, and L. W. Smith.
1989.
Abnormal alveolar epithelial repair associated with failure of resolution in experimental streptococcal pneumonia.
J. Pathol.
159:245-253[Medline].
|
| 63.
|
Roilides, E., and P. A. Pizzo.
1992.
Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts.
Clin. Infect. Dis.
15:508-524[Medline].
|
| 64.
|
Rubins, J. B.,
D. Charboneau,
J. C. Paton,
T. J. Mitchell,
P. W. Andrew, and E. N. Janoff.
1995.
Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia.
J. Clin. Invest.
95:142-150.
|
| 65.
|
Rubins, J. B.,
P. G. Duane,
D. Charboneau, and E. N. Janoff.
1992.
Toxicity of pneumolysin to pulmonary endothelial cells in vitro.
Infect. Immun.
60:1740-1746[Abstract/Free Full Text].
|
| 66.
|
Rubins, J. B.,
P. G. Duane,
D. Clawson,
D. Charboneau,
J. Young, and D. E. Niewoehner.
1993.
Toxicity of pneumolysin to pulmonary alveolar epithelial cells.
Infect. Immun.
61:1352-1358[Abstract/Free Full Text].
|
| 67.
|
Sauve, C.,
E. Azoulay-Dupuis,
P. Moine,
C. Darras-Joly,
V. Rieux,
C. Carbon, and J. P. Bedos.
1996.
Efficacies of cefotaxime and ceftriaxone in a mouse model of pneumonia induced by two penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae.
Antimicrob. Agents Chemother.
40:2829-2834[Abstract].
|
| 68.
|
Schall, T. J.
1994.
The chemokines, p. 419-460. In
A. W. Thomson (ed.), The cytokine handbook, 2nd ed.
Academic Press, San Diego, Calif.
|
| 69.
|
Simon, R. H., and R. Paine.
1995.
Participation of pulmonary alveolar epithelial cells in lung inflammation.
J. Lab. Clin. Med.
126:108-118[Medline].
|
| 70.
|
Simpson, S. Q., and L. C. Casey.
1989.
Role of tumor necrosis factor in sepsis and acute lung injury.
Crit. Care Clin.
5:27-47[Medline].
|
| 71.
|
Skerrett, S. J.
1994.
Host defenses against respiratory infection, p. 941-966. In
M. S. Niederman (ed.), The medical clinics of North America. Pneumonia: pathogenesis, diagnosis and management. W. B.
Saunders Company, Montreal, Québec, Canada.
|
| 72.
|
Snyder, S. H., and D. S. Bredt.
1992.
Biological roles of nitric oxide.
Sci. Am.
266:68-77[Medline].
|
| 73.
|
Standiford, T. J.,
S. L. Kunkel,
M. A. Basha,
S. W. Chensue,
J. P. Lynch,
G. B. Toews,
J. Westwick, and R. M. Strieter.
1990.
Interleukin-8 gene expression by a pulmonary epithelial cell line; a model for cytokine networks in the lung.
J. Clin. Invest.
86:1945-1953.
|
| 74.
|
Standiford, T. J.,
S. L. Kunkel,
M. J. Greenberger,
L. L. Laichalk, and R. M. Strieter.
1996.
Expression and regulation of chemokines in bacterial pneumonia.
J. Leukocyte Biol.
59:24-28[Abstract].
|
| 75.
|
Su, T. H., and W. J. Martin.
1994.
Pathogenesis and host response in Pneumocystis carinii pneumonia.
Annu. Rev. Med.
45:261-272[Medline].
|
| 76.
|
Sugawara, T.,
M. Miyamoto,
S. Takayama, and M. Kato.
1995.
Separation of neutrophils from blood in human and laboratory animals and comparison of the chemotaxis.
J. Pharmacol. Toxicol. Methods
33:91-100[Medline].
|
| 77.
|
Takashima, K.,
K. Tateda,
T. Matsumoto,
Y. Iizawa,
M. Nakao, and K. Yamaguchi.
1997.
Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice.
Infect. Immun.
65:257-260[Abstract].
|
| 78.
|
Takashima, K.,
K. Tateda,
T. Matsumoto,
T. Ito,
Y. Iizawa,
M. Nakao, and K. Yamaguchi.
1996.
Establishment of a model of penicillin-resistant Streptococcus pneumoniae pneumonia in healthy CBA/J mice.
J. Med. Microbiol.
45:319-322[Abstract].
|
| 79.
|
Talbot, U. M.,
A. W. Paton, and J. C. Paton.
1996.
Uptake of Streptococcus pneumoniae by respiratory epithelial cells.
Infect. Immun.
64:3772-3777[Abstract].
|
| 80.
|
Terada, L. S., and J. E. Repine.
1992.
Oxygen radicals and lung disease, p. 159-174. In
A. P. Fishman (ed.), Update: pulmonary diseases and disorders.
McGraw-Hill, Montreal, Québec, Canada.
|
| 81.
|
Tsai, W. C.,
R. M. Strieter,
D. A. Zisman,
J. M. Wilkowski,
K. A. Bucknell,
G. H. Chen, and T. J. Standiford.
1997.
Nitric oxide is required for effective innate immunity against Klebsiella pneumoniae.
Infect. Immun.
65:1870-1875[Abstract].
|
| 82.
|
Tuomanen, E. I.,
R. Austrian, and H. R. Masure.
1995.
Pathogenesis of pneumococcal infection.
N. Engl. J. Med.
332:1280-1284[Free Full Text].
|
| 83.
|
Ulich, T. R.,
L. R. Watson,
S. Yin,
K. Guo,
P. Wang,
H. Thang, and J. D. Castillo.
1991.
The intratracheal administration of endotoxin and cytokines. I. Characterization of LPS-induced IL-1 and TNF mRNA expression and the LPS-, IL-1, and TNF-induced inflammatory infiltrate.
Am. J. Pathol.
138:1485-1496 |